Nebivolol hydrochloride

Research use only, not for human use.

Nebivolol hydrochloride selectively inhibits?β1- adrenergic receptor with?IC50?of 0.8 nM.

Nebivolol hydrochloride selectively inhibits?β1- adrenergic receptor with?IC50?of 0.8 nM.(In Vitro):Nebivolol hydrochloride improves endothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase and via its antioxidative properties.Nebivolol hydrochloride (0.1 μM-10 μM, 1, 2, 4, 7 or 14 days) inhibits haCSMC or haEC proliferation with IC50 values of ~ 6.0 μM.Nebivolol hydrochloride (0.1 μM-10 μM, 24 h) induces a moderate rate of apoptosis.Nebivolol hydrochloride (0.1, 1, 5,10 μM, 4 days)increases NO formation and decreases endothelin-1 secretion in HaCEs

Cell Proliferation Assay Cell Line:haCSMCs (human coronary smooth muscle cells) and haECs (endothelial cells)Concentration:0.1 μM-10 μM Incubation Time:1, 2, 4, 7 or 14 days Result:Reduced proliferation in HaECs and HaCSMCs in a concentration- and time-dependent.Apoptosis Analysis Cell Line:haCSMCs and haECs Concentration:0.1 μM-10 μM Incubation Time:24 h Result:Induced a moderate apoptosis in concentration-dependent and showed a decrease of haCSMCs in the S-phase by 66%.

——

Nebivolol HCl | Nebivolol Hydrochloride | Silostar | Bystolic, R-67145 | R 67145 | R67145

Endocrinology/Hormones

Adrenergic Receptor

β1-adrenoceptor

Cardiovascular Disease

——

152520-56-4

441.9

C22H25F2NO4·HCl

>98% (HPLC)

DMSO: 88 mg/mL (199.14 mM)

O[C@@H]([C@H]1CCC2=C(O1)C=CC(F)=C2)CNC[C@H](O)[C@@H]3CCC4=C(O3)C=CC(F)=C4.[H]Cl

(R)-1-((R)-6-fluorochroman-2-yl)-2-(((S)-2-((S)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethan-1-ol hydrochloride

(-20℃)

With Ice Pack

≥ 2 years